CA2478931A1 - A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus - Google Patents
A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus Download PDFInfo
- Publication number
- CA2478931A1 CA2478931A1 CA002478931A CA2478931A CA2478931A1 CA 2478931 A1 CA2478931 A1 CA 2478931A1 CA 002478931 A CA002478931 A CA 002478931A CA 2478931 A CA2478931 A CA 2478931A CA 2478931 A1 CA2478931 A1 CA 2478931A1
- Authority
- CA
- Canada
- Prior art keywords
- phytostanol
- group
- insulin
- phytosterol
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9874502A | 2002-03-14 | 2002-03-14 | |
US10/098,745 | 2002-03-14 | ||
PCT/CA2003/000369 WO2003075931A1 (en) | 2002-03-14 | 2003-03-14 | A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2478931A1 true CA2478931A1 (en) | 2003-09-18 |
Family
ID=27804294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002478931A Abandoned CA2478931A1 (en) | 2002-03-14 | 2003-03-14 | A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1482950A1 (pt) |
JP (1) | JP2005528353A (pt) |
KR (1) | KR20040104513A (pt) |
CN (1) | CN1681514A (pt) |
AU (1) | AU2003218547B2 (pt) |
BR (1) | BR0308396A (pt) |
CA (1) | CA2478931A1 (pt) |
NO (1) | NO20044346L (pt) |
NZ (1) | NZ535200A (pt) |
RU (1) | RU2334518C2 (pt) |
WO (1) | WO2003075931A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080182801A1 (en) | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
GB0329667D0 (en) | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
GB0513881D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
GB0513883D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Diagnosis of Atherosclerosis |
GB0513888D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
AU2010298733B2 (en) * | 2009-09-28 | 2014-10-09 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
AU2016314373A1 (en) * | 2015-09-03 | 2018-03-29 | Natural Shield Israel 2016 Ltd | Combined compositions for controlling blood sugar levels, hepatoprotection, and for prevention and treatment of related medical conditions |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001000653A1 (en) * | 1999-06-23 | 2001-01-04 | Forbes Medi-Tech Inc. | Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease |
-
2003
- 2003-03-14 CN CNA038059738A patent/CN1681514A/zh active Pending
- 2003-03-14 CA CA002478931A patent/CA2478931A1/en not_active Abandoned
- 2003-03-14 NZ NZ535200A patent/NZ535200A/en unknown
- 2003-03-14 WO PCT/CA2003/000369 patent/WO2003075931A1/en active Application Filing
- 2003-03-14 RU RU2004130463/14A patent/RU2334518C2/ru not_active IP Right Cessation
- 2003-03-14 AU AU2003218547A patent/AU2003218547B2/en not_active Ceased
- 2003-03-14 JP JP2003574205A patent/JP2005528353A/ja active Pending
- 2003-03-14 BR BR0308396-9A patent/BR0308396A/pt not_active IP Right Cessation
- 2003-03-14 EP EP03711733A patent/EP1482950A1/en not_active Withdrawn
- 2003-03-14 KR KR10-2004-7014408A patent/KR20040104513A/ko not_active Application Discontinuation
-
2004
- 2004-10-13 NO NO20044346A patent/NO20044346L/no unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003218547B2 (en) | 2007-11-01 |
NZ535200A (en) | 2007-07-27 |
BR0308396A (pt) | 2005-01-11 |
RU2334518C2 (ru) | 2008-09-27 |
AU2003218547A1 (en) | 2003-09-22 |
NO20044346L (no) | 2004-12-09 |
RU2004130463A (ru) | 2005-04-10 |
KR20040104513A (ko) | 2004-12-10 |
EP1482950A1 (en) | 2004-12-08 |
CN1681514A (zh) | 2005-10-12 |
JP2005528353A (ja) | 2005-09-22 |
WO2003075931A1 (en) | 2003-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1227734B1 (en) | Compositions comprising edible oils or fats and phytosterols and/or phytostanols dissolved therein | |
US8071558B2 (en) | Application of D-psicose to suppression of abnormal circadian increase in blood glucose level | |
US20020156051A1 (en) | Novel structures comprising phytosterol and/or phytostanol and ascorbic acid and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders | |
US20030203854A1 (en) | Composition for effecting serum cholesterol levels | |
AU2003218547B2 (en) | A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus | |
US9642875B2 (en) | Compounds and their effects on appetite control and insulin sensitivity | |
JP2008222656A (ja) | 肥満改善および予防用組成物ならびに健康食品 | |
WO2001066560A2 (en) | Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders | |
EP1644007B1 (en) | Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type ii diabetes | |
US20100286104A1 (en) | Agent for inhibiting visceral fat accumulation | |
JP2001278804A (ja) | 脂質代謝改善剤及びそれを含有する食品 | |
KR100886466B1 (ko) | 신규한 스티그마스테롤 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법, 및 이를 포함하는 비만억제 또는 고지혈증 예방 및 치료용 조성물 | |
WO2004014159A1 (en) | Method of lowering glycaemic index of foods | |
EP1333838B1 (en) | Compounds comprising a phytosterol and/or phytostanol moiety and ascorbic acid and use thereof as weight regulating agents | |
EP1250350B1 (en) | Novel crystalline composites comprising phytosterols and phytostanols or derivatives thereof | |
CN115038435A (zh) | 肥胖抑制用组合物 | |
JP6770726B1 (ja) | メタボリックシンドロームの予防または改善剤 | |
JPH0410448B2 (pt) | ||
DE60218165T2 (de) | Lipolyseförderer zur Reduzierung des Körpergewichts und medizinische Anwendung | |
AU2007203095A1 (en) | Compounds comprising a phytosterol and/or phytostanol moiety and ascorbis acid and use thereof as weight regulating agents | |
CA2461136A1 (en) | A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl) | |
KR20040017891A (ko) | 레반을 이용한 비만 개선 식이 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |